Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

TP53 outperforms other androgen receptor biomarkers to predict abiraterone or enzalutamide outcome in metastatic castration-resistant prostate cancer.

De Laere B, Oeyen S, Mayrhofer M, Whitington T, van Dam PJ, Van Oyen P, Ghysel C, Ampe J, Ost P, Demey W, Hoekx L, Schrijvers D, Brouwers B, Lybaert W, Everaert EG, De Maeseneer D, Strijbos M, Bols A, Fransis K, Beije N, de Kruijff IE, van Dam V, Brouwer A, Goossens D, Heyrman L, Van den Eynden GG, Rutten A, Del Favero J, Rantalainen M, Rajan P, Sleijfer S, Ullén A, Yachnin J, Grönberg H, Van Laere SJ, Lindberg J, Dirix LY.

Clin Cancer Res. 2018 Sep 12. pii: clincanres.1943.2018. doi: 10.1158/1078-0432.CCR-18-1943. [Epub ahead of print]

PMID:
30209161
2.

Circulating tumor cells and survival in abiraterone- and enzalutamide-treated patients with castration-resistant prostate cancer.

De Laere B, Oeyen S, Van Oyen P, Ghysel C, Ampe J, Ost P, Demey W, Hoekx L, Schrijvers D, Brouwers B, Lybaert W, Everaert E, Van Kerckhove P, De Maeseneer D, Strijbos M, Bols A, Fransis K, Beije N, de Kruijff I, van Dam V, Brouwer A, van Dam PJ, Van den Eynden G, Rutten A, Sleijfer S, Vandebroek J, Van Laere S, Dirix L.

Prostate. 2018 May;78(6):435-445. doi: 10.1002/pros.23488. Epub 2018 Feb 12.

PMID:
29431193
3.

Which Factors Predict Overall Survival in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Abiraterone Acetate Post-Docetaxel?

Van Praet C, Rottey S, Van Hende F, Pelgrims G, Demey W, Van Aelst F, Wynendaele W, Gil T, Schatteman P, Filleul B, Schallier D, Machiels JP, Schrijvers D, Everaert E, D'Hondt L, Werbrouck P, Vermeij J, Mebis J, Clausse M, Rasschaert M, Van Erps J, Verheezen J, Van Haverbeke J, Goeminne JC, Lumen N.

Clin Genitourin Cancer. 2017 Aug;15(4):502-508. doi: 10.1016/j.clgc.2017.01.019. Epub 2017 Feb 1.

PMID:
28258960
4.

Abiraterone acetate post-docetaxel for metastatic castration-resistant prostate cancer in the Belgian compassionate use program.

Van Praet C, Rottey S, Van Hende F, Pelgrims G, Demey W, Van Aelst F, Wynendaele W, Gil T, Schatteman P, Filleul B, Schallier D, Machiels JP, Schrijvers D, Everaert E, D'Hondt L, Werbrouck P, Vermeij J, Mebis J, Clausse M, Rasschaert M, Van Erps J, Verheezen J, Van Haverbeke J, Goeminne JC, Lumen N.

Urol Oncol. 2016 Jun;34(6):254.e7-254.e13. doi: 10.1016/j.urolonc.2015.12.017. Epub 2016 Feb 2.

PMID:
26850781
5.

An unexpected hazard in the Arctic region.

Verhoeven V, Demey W, Naveau P, Storms G, Ledeganck P, Beyens L.

J Travel Med. 2007 Nov-Dec;14(6):417. No abstract available.

6.

Intra-hepatic Mitomycin C bolus infusion in the treatment of extensive liver metastases of breast cancer.

Maes T, Wildiers H, Heye S, Demey W, Maleux G, Neven P, Van Oosterom AT, Paridaens R.

Breast Cancer Res Treat. 2008 Jul;110(1):135-42. Epub 2007 Sep 13.

PMID:
17851764
7.

Recurrent low- to intermediate-grade chondrosarcoma of the thumb with lung metastases: an objective response to trofosfamide.

Debruyne PR, Dumez H, Demey W, Gillis L, Sciot R, Schöffski P.

Onkologie. 2007 Apr;30(4):201-4. Epub 2007 Mar 23.

PMID:
17396043
8.

From prolonged febrile illness to fever of unknown origin: the challenge continues.

Vanderschueren S, Knockaert D, Adriaenssens T, Demey W, Durnez A, Blockmans D, Bobbaers H.

Arch Intern Med. 2003 May 12;163(9):1033-41.

PMID:
12742800

Supplemental Content

Support Center